Literature DB >> 7821045

[Therapy of unilobar Caroli syndrome by liver resection].

M Knoop1, H Keck, J M Langrehr, F J Peter, B Ferslev, P Neuhaus.   

Abstract

Caroli's disease is characterized by uni- or bilobar cystic enlargement of the intrahepatic biliary tract. Clinical symptoms include recurrent cholangitis, right upper quadrant abdominal pain and jaundice. The diagnosis is usually established preoperatively based on abdominal ultrasound, computertomography and ERCP. Eight patients suffering from unilobar Caroli's disease underwent liver resection during a period of six years. The postoperative course was uneventful, and after a median follow-up of 39.6 months in one case only a temporary jaundice occurred. Liver resection is the method of choice for Caroli's syndrome when feasible. Apart from the curative intention liver resection represents also a prophylactic method since the risk of malignant transformation to cholangiocellular carcinoma in the cystic walls after draining procedures is considerably high. For diffuse spread of Caroli's disease in the liver orthotopic liver transplantation has emerged as therapeutic option.

Entities:  

Mesh:

Year:  1994        PMID: 7821045

Source DB:  PubMed          Journal:  Chirurg        ISSN: 0009-4722            Impact factor:   0.955


  2 in total

1.  Bile duct cyst type V (Caroli's disease): surgical strategy and results.

Authors:  Javier Lendoire; Pablo Barros Schelotto; Juan Alvarez Rodríguez; Fernando Duek; Carlos Quarin; Verónica Garay; Marcelo Amante; Eduardo Cassini; Oscar Imventarza
Journal:  HPB (Oxford)       Date:  2007       Impact factor: 3.647

2.  Congenital intrahepatic bile duct dilatation is a potentially curable disease: long-term results of a multi-institutional study.

Authors:  Jean-Yves Mabrut; Christian Partensky; Daniel Jaeck; Elie Oussoultzoglou; Jacques Baulieux; Olivier Boillot; Jan Lerut; Jean de Ville de Goyet; Catherine Hubert; Jean-Bernard Otte; Maxime Audet; Christian Ducerf; Jean-François Gigot
Journal:  Ann Surg       Date:  2007-08       Impact factor: 12.969

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.